Solesence Q1 Financial Performance Review
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Source: seekingalpha
- Financial Highlights: Solesence reported a Q1 GAAP EPS of -$0.01 with revenues of $13 million, indicating a net loss of approximately $0.8 million compared to a net income of $0.08 million in the same period of 2025, reflecting ongoing profitability challenges.
- Gross Profit Performance: The gross profit for Q1 was $3.3 million, with a gross margin of 26%, an improvement from 23% in the same period of 2025, suggesting progress in cost management and operational efficiency.
- Future Goals: Solesence aims for a 30% gross margin floor by 2026, targeting a 5% lift in gross margin under its Transform and Transcend strategy, which could positively impact the company's long-term profitability if achieved.
- Market Reaction: Despite revenue growth, the widening net loss may negatively affect investor confidence, particularly as the company has yet to achieve profitability, making future financial performance a focal point for stakeholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLSN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLSN
About SLSN
Solesence, Inc., formerly Nanophase Technologies Corporation, provides healthcare solutions across beauty and life science categories. It is a developer and manufacturer of clean, inclusive, mineral-based skincare and makeup products. The Company partners with global and indie brands, leveraging its proprietary Active Stress Defense technology suite (Original Active Stress Defense, Kleair, and Bloom) to bring environmental protection beauty products to market via over a dozen market-ready offerings that embrace self-expression, health care, and self-care across skin care and color cosmetic categories. It also offers custom development, with turnkey options available across all paths to market. The Company’s products are formulated using its own mineral sunscreen actives, which are produced in its Chicagoland facility where it has been producing sunscreen actives, including the zinc oxide sunscreen active.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Solésence's Day Mode Hero Concealer Wins Multiple Awards
- Award Recognition: Solésence's Day Mode Hero Concealer SPF 50+ has been recognized across three categories—Anti-Aging, Color Cosmetics, and Compromised Skin—at the 2026 C&T Allē Awards, marking the company's fourth consecutive year of accolades, which underscores its innovative prowess and market impact in the beauty industry.
- Technological Innovation: The concealer leverages three proprietary technologies—Kleair™, WHSPR™, and Chromalüm™—to deliver a daily-use product that not only provides skincare and sun protection but also pushes the boundaries of skincare, sun care, and makeup categories through the inclusion of OTC actives, meeting consumer demand for high-performance products.
- Market Opportunities: CEO Kevin Cureton highlighted that this product exemplifies how technology platforms can be translated into new market opportunities, addressing the evolving needs of beauty consumers and further solidifying Solésence's leadership position in the industry.
- Industry Recognition: The C&T Allē Awards evaluate criteria such as novelty, practicality, and efficacy, and Solésence's consecutive wins not only enhance brand reputation but also lay a foundation for future product development and market expansion.
See More
UK Calls for National UV Safety Strategy
- Report Release: The UK's All-Party Parliamentary Group (APPG) for Beauty, Hair & Wellbeing released a report on May 13 after a year-long inquiry into UV safety, highlighting the absence of a cohesive national strategy to address UV radiation, with melanoma cases projected to rise by 9% by 2038.
- Government Initiative: APPG Chair Carolyn Harris calls for a national campaign to shift public perception of UV protection, advocating for a sustained effort similar to Australia's successful initiatives, emphasizing that UV safety should be integrated into daily life.
- Collaborative Efforts: The report outlines 29 recommendations aimed at enhancing public awareness of skin health and UV protection through education and outreach, with Solésence, a member of the UV Safety Coalition, pledging to support the implementation of these non-governmental recommendations.
- Health Impact: Solésence's Executive Director Emma Harper stated that the multi-faceted recommendations in the report have the potential to improve human health and longevity, underscoring the company's commitment to providing skin health solutions tailored to diverse consumer needs.
See More
Solesence Q1 2026 Earnings Call Insights
- Revenue Performance: Solesence reported Q1 2026 revenue of $13 million, down from $14.6 million in Q1 2025, primarily due to shipping delays impacting OTIF performance, indicating ongoing challenges in operational execution.
- Margin Improvement: Despite the revenue decline, gross margin increased by 300 basis points to 26%, driven by improved labor efficiency and the elimination of product quality-related waste, showcasing positive progress in cost control measures.
- New Technology Launch: The company announced the launch of two new technologies, Chromalum and WHSPR, aimed at expanding its product line into hair and scalp care, indicating Solesence's proactive approach to innovation and enhancing market competitiveness.
- Full-Year Outlook: Management reiterated full-year guidance, expecting to maintain a 30% gross margin floor and return to double-digit EBITDA margins by year-end, reflecting confidence in future performance improvements.
See More
Solesence Q1 Financial Performance Review
- Financial Highlights: Solesence reported a Q1 GAAP EPS of -$0.01 with revenues of $13 million, indicating a net loss of approximately $0.8 million compared to a net income of $0.08 million in the same period of 2025, reflecting ongoing profitability challenges.
- Gross Profit Performance: The gross profit for Q1 was $3.3 million, with a gross margin of 26%, an improvement from 23% in the same period of 2025, suggesting progress in cost management and operational efficiency.
- Future Goals: Solesence aims for a 30% gross margin floor by 2026, targeting a 5% lift in gross margin under its Transform and Transcend strategy, which could positively impact the company's long-term profitability if achieved.
- Market Reaction: Despite revenue growth, the widening net loss may negatively affect investor confidence, particularly as the company has yet to achieve profitability, making future financial performance a focal point for stakeholders.
See More
Solésence Appoints Marc James to Board of Directors
- New Board Member: Solésence, Inc. has appointed Marc James as an independent director, effective immediately, aiming to enhance corporate governance and board expertise to support its Transform & Transcend strategic objectives.
- Rich Professional Background: James brings extensive experience in global financial markets, having served as a senior managing director focused on capital markets activities and financing strategies, which will provide crucial strategic insights and leadership for Solésence's growth strategy.
- Committee Involvement: Marc James will also serve on the Audit, Compensation, and Nominating Committees, which not only strengthens corporate governance but also ensures disciplined execution and operational excellence in pursuing growth strategies.
- Long-term Value Creation: James expressed his eagerness to collaborate with the board and management team, leveraging his expertise to drive innovation in the beauty and skin health sectors, thereby creating long-term value for shareholders.
See More
Solesence, Inc. Q4 2025 Earnings Call Insights
- Financial Performance Overview: Solesence reported Q4 2025 revenue of $12.5 million and gross profit of $3.4 million, with a gross margin of 27%, reflecting financial pressure due to transition costs and operational inefficiencies from facility consolidation, resulting in a net income of $163,000.
- Strategic Plan Announcement: CEO Kevin Cureton emphasized that 2026 will be an execution-focused year with the launch of the 'Transform and Transcend' initiative, aimed at enhancing product design, labor efficiency, and inventory control to achieve profitable growth, which is expected to bolster the company's competitive position in the market.
- Leadership Changes: The company appointed Laura Riffner as CFO in September 2025 and added Yoolie Park as Vice President of Brand Partnerships, reflecting a strategic focus on leveraging new leadership to drive profitable growth and effective execution of the company's plans.
- Future Outlook: CFO Riffner set a 30% gross margin target for 2026 and anticipates improving free cash flow through working capital actions, despite facing near-term pressures from changes in customer order patterns and weak sell-through from a large mass-market customer.
See More
Solésence's Day Mode Hero Concealer Wins Multiple Awards
- Award Recognition: Solésence's Day Mode Hero Concealer SPF 50+ has been recognized across three categories—Anti-Aging, Color Cosmetics, and Compromised Skin—at the 2026 C&T Allē Awards, marking the company's fourth consecutive year of accolades, which underscores its innovative prowess and market impact in the beauty industry.
- Technological Innovation: The concealer leverages three proprietary technologies—Kleair™, WHSPR™, and Chromalüm™—to deliver a daily-use product that not only provides skincare and sun protection but also pushes the boundaries of skincare, sun care, and makeup categories through the inclusion of OTC actives, meeting consumer demand for high-performance products.
- Market Opportunities: CEO Kevin Cureton highlighted that this product exemplifies how technology platforms can be translated into new market opportunities, addressing the evolving needs of beauty consumers and further solidifying Solésence's leadership position in the industry.
- Industry Recognition: The C&T Allē Awards evaluate criteria such as novelty, practicality, and efficacy, and Solésence's consecutive wins not only enhance brand reputation but also lay a foundation for future product development and market expansion.
See More
UK Calls for National UV Safety Strategy
- Report Release: The UK's All-Party Parliamentary Group (APPG) for Beauty, Hair & Wellbeing released a report on May 13 after a year-long inquiry into UV safety, highlighting the absence of a cohesive national strategy to address UV radiation, with melanoma cases projected to rise by 9% by 2038.
- Government Initiative: APPG Chair Carolyn Harris calls for a national campaign to shift public perception of UV protection, advocating for a sustained effort similar to Australia's successful initiatives, emphasizing that UV safety should be integrated into daily life.
- Collaborative Efforts: The report outlines 29 recommendations aimed at enhancing public awareness of skin health and UV protection through education and outreach, with Solésence, a member of the UV Safety Coalition, pledging to support the implementation of these non-governmental recommendations.
- Health Impact: Solésence's Executive Director Emma Harper stated that the multi-faceted recommendations in the report have the potential to improve human health and longevity, underscoring the company's commitment to providing skin health solutions tailored to diverse consumer needs.
See More
Solesence Q1 2026 Earnings Call Insights
- Revenue Performance: Solesence reported Q1 2026 revenue of $13 million, down from $14.6 million in Q1 2025, primarily due to shipping delays impacting OTIF performance, indicating ongoing challenges in operational execution.
- Margin Improvement: Despite the revenue decline, gross margin increased by 300 basis points to 26%, driven by improved labor efficiency and the elimination of product quality-related waste, showcasing positive progress in cost control measures.
- New Technology Launch: The company announced the launch of two new technologies, Chromalum and WHSPR, aimed at expanding its product line into hair and scalp care, indicating Solesence's proactive approach to innovation and enhancing market competitiveness.
- Full-Year Outlook: Management reiterated full-year guidance, expecting to maintain a 30% gross margin floor and return to double-digit EBITDA margins by year-end, reflecting confidence in future performance improvements.
See More
Solesence Q1 Financial Performance Review
- Financial Highlights: Solesence reported a Q1 GAAP EPS of -$0.01 with revenues of $13 million, indicating a net loss of approximately $0.8 million compared to a net income of $0.08 million in the same period of 2025, reflecting ongoing profitability challenges.
- Gross Profit Performance: The gross profit for Q1 was $3.3 million, with a gross margin of 26%, an improvement from 23% in the same period of 2025, suggesting progress in cost management and operational efficiency.
- Future Goals: Solesence aims for a 30% gross margin floor by 2026, targeting a 5% lift in gross margin under its Transform and Transcend strategy, which could positively impact the company's long-term profitability if achieved.
- Market Reaction: Despite revenue growth, the widening net loss may negatively affect investor confidence, particularly as the company has yet to achieve profitability, making future financial performance a focal point for stakeholders.
See More
Solésence Appoints Marc James to Board of Directors
- New Board Member: Solésence, Inc. has appointed Marc James as an independent director, effective immediately, aiming to enhance corporate governance and board expertise to support its Transform & Transcend strategic objectives.
- Rich Professional Background: James brings extensive experience in global financial markets, having served as a senior managing director focused on capital markets activities and financing strategies, which will provide crucial strategic insights and leadership for Solésence's growth strategy.
- Committee Involvement: Marc James will also serve on the Audit, Compensation, and Nominating Committees, which not only strengthens corporate governance but also ensures disciplined execution and operational excellence in pursuing growth strategies.
- Long-term Value Creation: James expressed his eagerness to collaborate with the board and management team, leveraging his expertise to drive innovation in the beauty and skin health sectors, thereby creating long-term value for shareholders.
See More
Solesence, Inc. Q4 2025 Earnings Call Insights
- Financial Performance Overview: Solesence reported Q4 2025 revenue of $12.5 million and gross profit of $3.4 million, with a gross margin of 27%, reflecting financial pressure due to transition costs and operational inefficiencies from facility consolidation, resulting in a net income of $163,000.
- Strategic Plan Announcement: CEO Kevin Cureton emphasized that 2026 will be an execution-focused year with the launch of the 'Transform and Transcend' initiative, aimed at enhancing product design, labor efficiency, and inventory control to achieve profitable growth, which is expected to bolster the company's competitive position in the market.
- Leadership Changes: The company appointed Laura Riffner as CFO in September 2025 and added Yoolie Park as Vice President of Brand Partnerships, reflecting a strategic focus on leveraging new leadership to drive profitable growth and effective execution of the company's plans.
- Future Outlook: CFO Riffner set a 30% gross margin target for 2026 and anticipates improving free cash flow through working capital actions, despite facing near-term pressures from changes in customer order patterns and weak sell-through from a large mass-market customer.
See More
